Autoimmune Disease Clinical Trials in Wuhan, Hubei
6 recruitingWuhan, Hubei, China
Showing 1–6 of 6 trials
Recruiting
Not Applicable
CAR-T Therapy for Refractory Autoimmune Diseases
Autoimmune Diseases
LiangZou20 enrolled1 locationNCT07059169
Recruiting
Early Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
Autoimmune Diseases
Ruijin Hospital66 enrolled3 locationsNCT06747156
Recruiting
Phase 1
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Neurological Autoimmune Diseases
Grit Biotechnology30 enrolled1 locationNCT07021209
Recruiting
Not Applicable
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
Autoimmune Diseases of the Nervous System
Tongji Hospital20 enrolled1 locationNCT06797024
Recruiting
Early Phase 1
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557
Recruiting
Phase 4
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
PreventionAutoimmune DiseasesConnective Tissue Disease+2 more
Tongji Hospital800 enrolled1 locationNCT06499233